27th May 2020
NICE to resume publishing guidance
Final guidance approving the use of fremanezumab had been expected to be issued in April
Since mid-March, the National Institute for Health and Care Excellence (NICE) has had to focus a significant amount of its resources on supporting the health and care system with a new series of rapid Covid-19 related guidelines.
This led to it pausing or delaying all the appraisals of calcitonin gene-related peptide (CGRP) drug treatments for the prevention of migraine. It also meant that its final guidance approving the use on the NHS in England and Wales of fremanezumab (Ajovy) to treat chronic migraine, that was expected to be issued on 15 April 2020, wasn’t published.
Resume publishing guidance
As the NHS and wider health and care system starts to make arrangements for the next phase of its response to the pandemic, NICE has said that it will plan a phased restart of publishing draft and final guidance that had previously been de-prioritised from 1 June 2020.
This will therefore apply to the final approval of fremanezumab.
We welcome this development and will continue to monitor this situation closely. We will post an update when we learn more, particularly in relation to paused appraisals for other migraine treatments.